Oct 9, 2026 08:01AM
Oct 9, 2026 08:00AM
Aug 5, 2026 04:00PM
Jul 8, 2026 08:00AM
Jul 8, 2026 08:00AM
May 6, 2026 04:00PM
Feb 25, 2026 04:00PM Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Jan 12, 2026 08:10AM
Jan 12, 2026 08:00AM
Nov 17, 2025 08:04AM
Nov 17, 2025 08:00AM
Aug 6, 2025 04:00PM
Jun 26, 2025 08:00AM
Jun 10, 2025 08:00AM Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Jun 9, 2025 06:40AM
Jun 6, 2025 08:00AM
May 7, 2025 11:19AM
May 7, 2025 11:18AM
May 6, 2025 04:00PM
Mar 7, 2025 08:00AM
Feb 28, 2025 09:00AM Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Feb 26, 2025 08:02AM
Feb 26, 2025 08:00AM
Feb 25, 2025 04:00PM
Nov 6, 2024 04:00PM
Sep 24, 2024 08:00AM
Sep 24, 2024 08:00AM
Jul 9, 2024 08:43AM Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
Jul 9, 2024 08:00AM
Jun 10, 2024 02:31PM
Jun 10, 2024 02:30PM
May 15, 2024 07:15AM
May 14, 2024 04:00PM
Mar 10, 2024 04:00PM
Feb 27, 2024 05:50AM Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Jan 16, 2024 05:19AM
Jan 14, 2024 04:00AM
Nov 29, 2023 08:02AM
Nov 29, 2023 08:00AM
Apr 18, 2023 08:02AM
Apr 18, 2023 08:00AM
Apr 18, 2023 08:00AM Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Jul 7, 2022 06:15AM
Jun 6, 2022 08:41AM
Jun 6, 2022 07:30AM
Jun 6, 2022 07:30AM
Jun 6, 2022 07:30AM
May 5, 2022 04:01PM
May 5, 2022 04:01PM Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
Mar 28, 2022 10:28AM

15,970 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All